Skip to content

Application of indocyanine green fluorescence imaging in the treatment of secondary lymphedema

Application of indocyanine green fluorescence imaging in the treatment of secondary lymphedema

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073614
Enrollment
Unknown
Registered
2023-07-17
Start date
2023-07-17
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema

Interventions

Indocyanine green group:Within 12-24 hours before Lymphatic vessel vein anastomosis, 0.2ml indocyanine green solution (0.25% concentration) was injected subcutaneously between the first and second toe
control group:No intervention before Lymphatic vessel vein anastomosis

Sponsors

Beijing Shijitan Hospital affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Female aged 18-70; 2) Secondary lymphedema of unilateral lower limb; 3) Three to five months after the first stage liposuction volume reduction surgery, the second stage Lymphatic vessel vein anastomosis is planned; 4) Volunteer to participate in the experiment and sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1) Positive iodine allergy test; 2) Poor compliance and inability to treat according to the research protocol; 3) Unable to complete follow-up on schedule;

Design outcomes

Primary

MeasureTime frame
Lower limb circumference measurement value;

Secondary

MeasureTime frame
Limb moisture content measurement;Number of anastomosed Lymphatic vessel vessels;Frequency of erysipelas infection;Quality of life score;

Countries

Beijing

Contacts

Public ContactJianfeng Xin

Beijing Shijitan Hospital affiliated to Capital Medical University

xin2480@163.com+86 136 1101 6671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026